Advanced search×

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Christian C Asseburg, Martin M Frank, Claus-Henning CH Köhne, Jörg Thomas JT Hartmann, Ingolf I Griebsch, Andrea A Mohr, Ulrike U Osowski, Jeltje J Schulten, and Thomas T Mittendorf

Clin Ther 33(4):482-97 (2011) PMID 21635994

In patients with metastases limited to the liver (liver-limited disease [LLD]), effective therapies such as monoclonal antibodies combined with chemotherapy may facilitate metastasis resection and improve long-term survival.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.clinthera.2011.04.010
Version: za2963e q8zae q8zb2 q8zca q8zda q8ze3 q8zfe q8zg0

Similar articles you may find interesting…

  1. Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspective
    Prashant Satish Chikramane, Akkihebbal K Suresh, ... Shantaram Govind Kane

    Homeopathy 99(4):12 (2010) PMID 20970092

    We have demonstrated for the first time by Transmission Electron Microscopy (TEM), electron diffraction and chemical analysis by Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES), the presence of physical entities in these extreme dilutions, in the form of nanoparticles of the starti...
  2. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Sal...
    Gemma G Bruera and Enrico E Ricevuto

    Expert Opin Biol Ther 11(6):821-4 (2011) PMID 21545334

    This paper evaluates a recent study whereby a four-drug combination regimen adding bevacizumab to triplet fluorouracil, oxaliplatin and irinotecan chemotherapy is described for the first-line treatment of metastatic colorectal cancer. It extends the use of intensive medical treatment...
  3. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a...
    Gianluca Masi, Fotios Loupakis, ... Alfredo Falcone

    Lancet Oncol 11(9):8 (2010) PMID 20702138

    From July 2, 2007, to April 1, 2008, 57 patients were enrolled; all patients were assessed for safety and efficacy. Median follow-up time was 28.8 months (95% CI 24.9-32.5). PFS at 10 months was 74% (95% CI 62-85). Main grade 3 or 4 adverse events during induction treatment were neutropenia (n=28 [4...